6 years ago

Pathios Therapeutics Secures $8.8 Million Series A for Autoimmune and Cancer Therapies

  • Pathios Therapeutics, a UK-based biotech company, has raised US$8.8 million in Series A funding led by Canaan and Medical Research Commercialisation Fund

  • The company will use the funds to advance its development programs for therapies targeting autoimmune diseases and cancer

  • Pathios focuses on modulators of GPR65, a key mediator of immune system cell signaling in acidic pH environments

  • The company also appointed Stuart Hughes as its new CEO, bringing extensive experience in drug discovery and development.

      • ProblemHealthcare

      "Many immune diseases and cancers are caused by an overly acidic pH environment, which triggers harmful immune responses. This happens because GPR65, a protein highly expressed in immune cells, is activated by acidity. "

      Solution

      "Pathios Therapeutics develops medicines that target GPR65, a key protein in the immune system. By controlling GPR65 activity, their therapies aim to regulate immune responses and treat diseases like cancer and autoimmune disorders."

      Covered on